Yeter, H. H. Et Al. 2022. Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome. ROMANIAN JOURNAL OF INTERNAL MEDICINE , vol.60, no.1 , 56-65.

Yeter, H. H., Derici, Ü., Arinsoy, T., Altok, K., Erten, Y., & Güz, G., (2022). Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome. ROMANIAN JOURNAL OF INTERNAL MEDICINE , vol.60, no.1, 56-65.

Yeter, HACI Et Al. "Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome," ROMANIAN JOURNAL OF INTERNAL MEDICINE , vol.60, no.1, 56-65, 2022

Yeter, HACI H. Et Al. "Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome." ROMANIAN JOURNAL OF INTERNAL MEDICINE , vol.60, no.1, pp.56-65, 2022

Yeter, H. H. Et Al. (2022) . "Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome." ROMANIAN JOURNAL OF INTERNAL MEDICINE , vol.60, no.1, pp.56-65.

@article{article, author={HACI HASAN YETER Et Al. }, title={Discontinuation of Eculizumab treatment after hematological remission in patients with atypical and drug-induced hemolytic uremic syndrome}, journal={ROMANIAN JOURNAL OF INTERNAL MEDICINE}, year=2022, pages={56-65} }